$15.61
0.26% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
JE00BYSS4X48
Symbol
NVCR

Novocure Ltd. Stock price

$15.61
-2.39 13.28% 1M
+0.97 6.63% 6M
+0.68 4.55% YTD
-1.39 8.18% 1Y
-110.08 87.58% 3Y
-57.83 78.74% 5Y
-2.67 14.61% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.04 0.26%
ISIN
JE00BYSS4X48
Symbol
NVCR
Sector

Key metrics

Market capitalization $1.69b
Enterprise Value $1.41b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.57
P/S ratio (TTM) P/S ratio 3.08
P/B ratio (TTM) P/B ratio 4.67
Revenue growth (TTM) Revenue growth 8.33%
Revenue (TTM) Revenue $549.96m
EBIT (operating result TTM) EBIT $-176.34m
Free Cash Flow (TTM) Free Cash Flow $-104.47m
Cash position $954.83m
EPS (TTM) EPS $-1.57
P/E forward negative
P/S forward 2.92
EV/Sales forward 2.44
Short interest 6.88%
Show more

Is Novocure Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Novocure Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Novocure Ltd. forecast:

3x Buy
43%
4x Hold
57%

Analyst Opinions

7 Analysts have issued a Novocure Ltd. forecast:

Buy
43%
Hold
57%

Financial data from Novocure Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
550 550
8% 8%
100%
- Direct Costs 132 132
8% 8%
24%
418 418
8% 8%
76%
- Selling and Administrative Expenses 371 371
8% 8%
67%
- Research and Development Expense 212 212
4% 4%
39%
-165 -165
8% 8%
-30%
- Depreciation and Amortization 11 11
4% 4%
2%
EBIT (Operating Income) EBIT -176 -176
7% 7%
-32%
Net Profit -169 -169
3% 3%
-31%

In millions USD.

Don't miss a Thing! We will send you all news about Novocure Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novocure Ltd. Stock News

Neutral
Business Wire
19 days ago
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Present Real-World Data at ESMO 2024.
Neutral
The Motley Fool
21 days ago
The commercial-stage biotech's leader is stepping down. This change is effective on Jan. 1, 2025.
Positive
Seeking Alpha
2 months ago
Today, we take a look at NovoCure Limited, which develops and manufactures tumor treating fields devices for solid tumor cancers. The company has beat expectations for both its first and second quarter results in 2024 and is pushing to garner approval for additional indications. An analysis of NovoCure following its better than expected performance Q2 results Thursday follows in the paragraphs ...
More Novocure Ltd. News

Company Profile

NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Head office Jersey
CEO Asaf Danziger
Employees 1,453
Founded 2000
Website www.novocure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today